Division of Urology, University of Maryland Medical Center, Baltimore, Maryland 21201, USA.
J Endourol. 2011 Apr;25(4):559-62. doi: 10.1089/end.2010.0463. Epub 2011 Mar 7.
Renal fossa recurrence of renal-cell carcinoma (RCC) after radical nephrectomy historically necessitates open surgical resection. Cryoablation provides a minimally invasive alternative to open resection for local recurrence. We describe our experience with percutaneous cryoablation in three patients who were experiencing fossa recurrence.
We retrospectively reviewed medical records of three patients with renal fossa recurrence of RCC who were treated with percutaneous cryoablation.
Percutaneous cryoablation was well tolerated; no complications were noted, and patients were discharged within 23 hours. One patient needed an additional cryoablation procedure, and one patient underwent subsequent open extirpation. Metastatic disease developed in one patient, while the other two patients remain negative for disease by axial imaging and percutaneous biopsy. All patients are alive at 43 months (range 22-54 months).
Percutaneous cryoablation, a minimally invasive intervention, has low morbidity and may be offered as an alternative to extirpation, although long-term oncologic data are lacking.
根治性肾切除术后肾细胞癌（RCC）肾窝复发，历史上需要开放性手术切除。冷冻消融术为局部复发提供了一种微创的开放性切除替代方法。我们描述了 3 例接受经皮冷冻消融术治疗的肾窝 RCC 复发患者的经验。
我们回顾性分析了 3 例接受经皮冷冻消融术治疗的肾窝 RCC 复发患者的病历。
经皮冷冻消融术耐受良好；无并发症发生，患者在 23 小时内出院。1 例患者需要再次冷冻消融治疗，1 例患者随后行开放性切除术。1 例患者发生转移性疾病，而另外 2 例患者的轴向影像学和经皮活检仍无疾病。所有患者均存活 43 个月（范围 22-54 个月）。
经皮冷冻消融术是一种微创干预，具有较低的发病率，可作为切除术的替代方法，尽管缺乏长期的肿瘤学数据。
